A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy

被引：0

作者：

Nath, Karthik ^{[1
]}

Shekarkhand, Tala ^{[2
]}

Salcedo, Meghan ^{[2
]}

Derkach, Andriy ^{[3
]}

Rueda, Siobhan ^{[4
]}

Chansakul, Aisara ^{[5
]}

Hulcrantz, Malin ^{[2
]}

Korde, Neha ^{[2
]}

Shah, Urvi A. ^{[2
]}

Tan, Carlyn ^{[2
]}

Chung, David J. ^{[1
,6
]}

Lahoud, Oscar B. ^{[6
]}

Hassoun, Hani ^{[2
]}

Lesokhin, Alexander M. ^{[1
,2
]}

Landau, Heather J. ^{[6
]}

Shah, Gunjan ^{[1
,6
]}

Scordo, Michael ^{[1
,6
]}

Giralt, Sergio A. ^{[1
,6
]}

Usmani, Saad Z. ^{[1
,2
]}

Roshal, Mikhail ^{[7
]}

Landgren, Ola ^{[8
]}

Mailankody, Sham ^{[1
,2
,9
,10
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Cellular Therapy Serv, New York, NY USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY USA

[3] Mem Sloan Kettering Canc Ctr, Dept Biostat & Epidmiol, New York, NY USA

[4] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA

[5] Weill Cornell Med Coll, Emergency Dept, Div Emergency Med, New York, NY USA

[6] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, New York, NY USA

[7] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY USA

[8] Univ Miami, Sylvester Comprehens Canc Ctr, Myeloma Program, Miami, FL USA

[9] Mem Sloan Kettering Canc Ctr, Myeloma Serv, 1275 York Ave, New York, NY 10065 USA

[10] Mem Sloan Kettering Canc Ctr, Cellular Therapeut Serv, 1275 York Ave, New York, NY 10065 USA

来源：

LEUKEMIA & LYMPHOMA | 2022年 / 63卷 / 14期

关键词：

OUTCOMES;

D O I：

10.1080/10428194.2022.2131417

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3488 / 3492

页数：5

共 50 条

[31] Minimal residual disease testing after stem cell transplantation for multiple myeloma
Sherrod, A. M.
Hari, P.
Mosse, C. A.
Walker, R. C.
Cornell, R. F.
BONE MARROW TRANSPLANTATION, 2016, 51 (01) : 2 - 12
[32] Monitoring of minimal residual disease among multiple myeloma patients after autologous stem cell transplantation
Akhundova, F.
Mendeleeva, L.
Galtseva, I.
Pokrovskaya, O.
Urnova, E.
Parovichnikova, E.
Savchenko, V.
BONE MARROW TRANSPLANTATION, 2012, 47 : S258 - S259
[33] Safety of Subcutaneous Daratumumab/ Hyaluronidase after Intravenous Daratumumab for Patients with Multiple Myeloma
Copley, Melissa
Metheny, Leland
Klisovic, Rebecca B.
Malek, Ehsan
BLOOD, 2022, 140 : 13202 - 13203
[34] Minimal residual disease in multiple myeloma: current status
Ding, Hong
Xu, Juan
Lin, Zhimei
Huang, Jingcao
Wang, Fangfang
Yang, Yan
Cui, Yushan
Luo, Hongmei
Gao, Yuhan
Zhai, Xinyu
Pang, Weicui
Zhang, Li
Zheng, Yuhuan
BIOMARKER RESEARCH, 2021, 9 (01)
[35] MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA: IMAGING TECHNIQUES
Zamagni, E.
Tacchetti, P.
Pantani, L.
Mancuso, K.
Zannetti, B.
Rocchi, S.
Rizzello, I
Caratozzolo, I
Nanni, C.
Fanti, S.
Cavo, M.
HAEMATOLOGICA, 2018, 103 : 1 - 2
[36] Advances in minimal residual disease monitoring in multiple myeloma
Wijnands, Charissa
Noori, Somayya
van de Donk, Niels W. C. J.
VanDuijn, Martijn M.
Jacobs, Joannes F. M.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2023, 60 (07) : 518 - 534
[37] Molecular detection of minimal residual disease in multiple myeloma
Bai, Yinlei
Orfao, Alberto
Sang Chim, Chor
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (01) : 11 - 26
[38] Minimal residual disease in multiple myeloma: current status
Hong Ding
Juan Xu
Zhimei Lin
Jingcao Huang
Fangfang Wang
Yan Yang
Yushan Cui
Hongmei Luo
Yuhan Gao
Xinyu Zhai
Weicui Pang
Li Zhang
Yuhuan Zheng
Biomarker Research, 9
[39] Imaging Measurable (Minimal) Residual Disease in Multiple Myeloma
Bhutani M.
Usmani S.Z.
Taneja A.
Landgren O.
Current Radiology Reports, 4 (12)
[40] Role of minimal residual disease assessment in multiple myeloma
Szalat, Raphael E.
Anderson, Kenneth C.
Munshi, Nikhil C.
HAEMATOLOGICA, 2024, 109 (07) : 2049 - 2059

← 1 2 3 4 5 →